CA-HAI-SOLUTIONS
22.5.2023 12:01:33 CEST | Business Wire | Press release
Intellego Technologies and HAI Solutions are proud to announce a strategic partnership that is designed to improve the quality and safety of intravenous (IV) vascular access. The partnership combines Intellego's patented ultraviolet-sensitive ink as an indicator component in HAI Solutions' QIKcap™ technology to offer visible and verifiable IV port protection and provide confidence that the needle-free connector has been disinfected.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230522005235/en/
The QIKcap (TM) disposable IV luer access cap with Intellego’s chromatic ink changes from yellow to pink, providing visible indication that a sufficient dose of germicidal energy has been delivered by HAI Solutions QIKcap (TM) handheld UV-C disinfection device. (Photo: Business Wire)
The QIKcap Disinfection Device™ is a patented, handheld UV-C tool that is designed to irradiate the surface of an intravenous connector and intravenous access points to prevent microbial ingress. The specialized luer cap, known as QIKcap™, incorporates Intellego’s proprietary ink. When the QIKcap is irradiated with the UV-C handheld device, the cap changes color from yellow to pink, providing visible indication that a sufficient dose of germicidal energy has been delivered in as little as one second.
The development of the QIKcap Disinfection Device and QIKcap is designed to address the continued risk of bloodstream infections (BSI) and hospital onset bacteremia (HOB), which is any positive blood culture obtained 48 hours after admission. In the 2023 Hospital Safety Grade data that was released on May 3, 2023 by The Leapfrog Group, healthcare-associated infections (HAIs) spiked to a 5-year high in U.S. hospitals during the COVID-19 pandemic and remain high. The report noted that the average CLABSI standard infection ratio increased by 60%. HAIs including Methicillin-resistant Staphylococcus aureus (MRSA), central line bloodstream infections (CLABSI) and catheter-associated urinary tract infections (CAUTI) increase the length of hospitalization stays, add to costs and are the leading causes of death in the U.S.
This novel use of Intellego’s photochromic ink as an ingredient in a medical device is a first for the Swedish company that is best known for its product line, UVC Dosimeters. Used by OEMs, in academic research and in healthcare facilities around the world, UVC Dosimeters are the most trusted and reliable single-use UV indicators cards that provide visible measurement of germicidal ultraviolet energy delivered to surfaces.
According to Claes Lindahl, CEO of Intellego Technologies, “We are excited about the opportunity to expand the application of our proprietary ink technology in new and innovative ways to provide visible evidence of successful UV irradiation. Our partnership with HAI Solutions demonstrates our commitment to life-saving technologies and promoting the safety, efficacy and efficiency of ultraviolet disinfection applications.”
"We are thrilled to announce our new strategic partnership with Intellego Technologies,” said Nicholas Perrenoud, CEO of HAI Solutions. “By working together, we will be able to leverage our respective resources and capabilities to drive innovation, create new opportunities, and deliver even greater value to our stakeholders. We look forward to a successful and mutually beneficial partnership with Intellego."
About Intellego Technologies
Intellego Technologies is a research and development company, headquartered in Solna, Sweden. Founded in 2011, Intellego has grown to become the global leader in colorimetric indicators that are utilized worldwide to visually validate the dose of ultraviolet irradiation delivered to surfaces. Through its patented photochromic ink technology, Intellego manufactures standard and customized indicators that make the benefits of germicidal ultraviolet light visible and promotes the safe, effective and efficient use of UV applications. Intellego’s products support better outcomes with ultraviolet devices in healthcare, food and beverage manufacturing, environmental services, and more. For more information, visit Intellego-Technologies.com and UVCdosimeters.com.
About HAI Solutions
Based in Santa Barbara, CA, HAI Solutions is developing a novel and diverse platform of innovative intravenous therapy solutions targeting IV contamination which occurs in challenging medical segments like the Operating Room, Intensive Care Unit and Emergency Room. Founded in 2015, HAI Solutions believes in protecting every patient by advancing clinical care across the healthcare spectrum. For more information, please visit www.HAI-Solutions.com or Twitter @HAISolutions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230522005235/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom